» Articles » PMID: 35948948

Association Between Serum Insulin-like Growth Factor 1 and Locomotive Syndrome in Community-dwelling Older People

Overview
Publisher Biomed Central
Specialties Orthopedics
Physiology
Date 2022 Aug 10
PMID 35948948
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Locomotive syndrome (LS) is a condition in which mobility decreases, and it is known as a risk factor for elderly persons needing care in connection with sarcopenia and frailty. Prevention or delay of the onset of these diseases is important for preventing the need for care, and identification of biomarkers as indicators for appropriate intervention is useful. The present study aimed to clarify whether the serum insulin-like growth factor 1 (IGF-1) level, which has been reported to be related to sarcopenia and frailty, is related to LS.

Methods: The study participants were 133 elderly people living in a rural area in Japan. LS was assessed using Locomo-25, which is a self-administered questionnaire, and LS was defined as a Locomo-25 score ≥ 7 points. Serum IGF-1 and albumin levels were measured. A self-completed medical history questionnaire was used.

Results: On multiple linear regression analysis, age, IGF-1, osteoporosis, and osteoarthritis were significantly associated with the Locomo-25 score. The receiver-operating characteristic curve analysis of the IGF-1 level showed a threshold value of 82.0 ng/mL for discriminating non-LS and LS. The logistic regression analysis adjusted for osteoporosis, osteoarthritis, and the propensity score estimated from sex, age, and BMI showed that the odds ratio (OR) of the IGF-1 level for LS was 1.019 (95% confidence interval [CI], 1.002-1.039; p = 0.027), and the OR of IGF-1 ≤ 82 ng/mL for LS was 2.275 (95% CI 0.993-5.324; p = 0.052).

Conclusions: The present findings suggest that osteoporosis and osteoarthritis were associated with early LS, and a decrease of the serum IGF-1 level was a significant independent factor for early LS.

Citing Articles

Relationship between locomotive syndrome and advanced glycation end products measured by skin autofluorescence in community-dwelling patients: the Yakumo Study.

Ozawa Y, Takegami Y, Seki T, Osawa Y, Iida H, Okamoto M Nagoya J Med Sci. 2024; 86(2):314-325.

PMID: 38962408 PMC: 11219223. DOI: 10.18999/nagjms.86.2.314.


Clinical characteristics of locomotive syndrome categorised by the 25-question Geriatric Locomotive Function Scale: a systematic review.

Kobayashi T, Morimoto T, Shimanoe C, Ono R, Otani K, Mawatari M BMJ Open. 2023; 13(5):e068645.

PMID: 37192799 PMC: 10193047. DOI: 10.1136/bmjopen-2022-068645.

References
1.
Basualto-Alarcon C, Varela D, Duran J, Maass R, Estrada M . Sarcopenia and Androgens: A Link between Pathology and Treatment. Front Endocrinol (Lausanne). 2015; 5:217. PMC: 4270249. DOI: 10.3389/fendo.2014.00217. View

2.
Angulo J, El Assar M, Alvarez-Bustos A, Rodriguez-Manas L . Physical activity and exercise: Strategies to manage frailty. Redox Biol. 2020; 35:101513. PMC: 7284931. DOI: 10.1016/j.redox.2020.101513. View

3.
Yoshihara T, Ozaki H, Nakagata T, Natsume T, Kitada T, Ishihara Y . Association between locomotive syndrome and blood parameters in Japanese middle-aged and elderly individuals: a cross-sectional study. BMC Musculoskelet Disord. 2019; 20(1):104. PMC: 6417127. DOI: 10.1186/s12891-019-2480-9. View

4.
Cruz-Jentoft A, Baeyens J, Bauer J, Boirie Y, Cederholm T, Landi F . Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4):412-23. PMC: 2886201. DOI: 10.1093/ageing/afq034. View

5.
Onder G, Liperoti R, Russo A, Soldato M, Capoluongo E, Volpato S . Body mass index, free insulin-like growth factor I, and physical function among older adults: results from the ilSIRENTE study. Am J Physiol Endocrinol Metab. 2006; 291(4):E829-34. DOI: 10.1152/ajpendo.00138.2006. View